Maia Kayal
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Maia Kayal has a total of 243 co-authors. Here are the top co-authors by number of shared publications:
Sergey Khaitov
Department of Surgery, Icahn School of Medicine at Mount Sinai , New York, NY
17 shared publicationsAlexander Greenstein
Department of Surgery, Icahn School of Medicine at Mount Sinai , New York, NY
14 shared publicationsMichael Plietz
Department of Surgery, Icahn School of Medicine at Mount Sinai , New York, NY
14 shared publicationsPatricia Sylla
Department of Surgery, Icahn School of Medicine at Mount Sinai , New York, NY
14 shared publications- Marla C. Dubinsky
Icahn School of Medicine at Mount Sinai, New York, New York, USA
12 shared publications Marla C. Dubinsky
Department of Medicine, Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, 17 E. 102Nd Street, 5th Floor, New York, NY, USA
10 shared publications
Latest Publications
- Open Access
- 29 September 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1) , 30190
Expert-defined features remain competitive with foundation models in predicting Crohn’s-like disease of the pouch
Patients with ulcerative colitis (UC) who undergo ileal pouch–anal anastomosis (IPAA) remain at risk of Crohn’s-like disease of the pouch (CLDP), a major cause of pouch failure. Accurate preoperative risk stratification is challenging. We evaluated whether machine learning (ML) and electronic health record–based foundation models (EHR-FMs) could improve prediction of CLDP. We included UC patients who underwent IPAA at Mount Sinai Hospital (2007–2021) with at least one postoperative pouchoscopy. Two feature sets were tested: (1) expert-defined, chart-reviewed variables and (2) embeddings generated by Mamba FM on EHR data from Mount Sinai Data Warehouse (MSDW), which were pretrained on external data (Stanford Medicine), local data (MSDW), or hybrid fine-tuning (Stanford-MSDW). Features were modeled with eXtreme Gradient Boosting (XGBoost), performance assessed via nested cross-validation, and interpretability evaluated with SHapley Additive exPlanations (SHAP). CLDP occurred in 80/447 patients (17.9%) within a median of 2.97 [1.82; 5.43] years after surgery. The FM trained only on Stanford data performed poorly on our data (perplexity = 39.32), but local retraining improved performance (MSDW: 2.45), with further gains from hybrid fine-tuning (Stanford-MSDW: 2.13). Stanford-MSDW embeddings achieved the best FM-based results (macro F1 = 0.55, AUROC = 0.62). Chart-reviewed features showed numerically higher performance (macro F1 = 0.58, AUROC = 0.65). However, the difference was not statistically significant (F1 Score = 0.03, 95% CI −0.04, 0.11, p-value = 0.41). SHAP analyses highlighted age at surgery, BMI, disease duration, and colectomy severity as key predictors. To date, expert-defined, chart-reviewed features predicted CLDP comparably to current EHR-FM embeddings and remain the more interpretable option.
- 29 September 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1) , 30190
Open AccessExpert-defined features remain competitive with foundation models in predicting Crohn’s-like disease of the pouch
Patients with ulcerative colitis (UC) who undergo ileal pouch–anal anastomosis (IPAA) remain at risk of Crohn’s-like disease of the pouch (CLDP), a major cause of pouch failure. Accurate preoperative risk stratification is challenging. We evaluated whether machine learning (ML) and electronic health record–based foundation models (EHR-FMs) could improve prediction of CLDP. We included UC patients who underwent IPAA at Mount Sinai Hospital (2007–2021) with at least one postoperative pouchoscopy. Two feature sets were tested: (1) expert-defined, chart-reviewed variables and (2) embeddings generated by Mamba FM on EHR data from Mount Sinai Data Warehouse (MSDW), which were pretrained on external data (Stanford Medicine), local data (MSDW), or hybrid fine-tuning (Stanford-MSDW). Features were modeled with eXtreme Gradient Boosting (XGBoost), performance assessed via nested cross-validation, and interpretability evaluated with SHapley Additive exPlanations (SHAP). CLDP occurred in 80/447 patients (17.9%) within a median of 2.97 [1.82; 5.43] years after surgery. The FM trained only on Stanford data performed poorly on our data (perplexity = 39.32), but local retraining improved performance (MSDW: 2.45), with further gains from hybrid fine-tuning (Stanford-MSDW: 2.13). Stanford-MSDW embeddings achieved the best FM-based results (macro F1 = 0.55, AUROC = 0.62). Chart-reviewed features showed numerically higher performance (macro F1 = 0.58, AUROC = 0.65). However, the difference was not statistically significant (F1 Score = 0.03, 95% CI −0.04, 0.11, p-value = 0.41). SHAP analyses highlighted age at surgery, BMI, disease duration, and colectomy severity as key predictors. To date, expert-defined, chart-reviewed features predicted CLDP comparably to current EHR-FM embeddings and remain the more interpretable option.
- 5 August 2026
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 20 (8)
Comparative risk of postoperative complications in ulcerative colitis patients following preoperative advanced therapies: a network meta-analysis with meta-regression
Background: The expanding use of biologic and small-molecule therapies for ulcerative colitis (UC) has raised concerns regarding perioperative safety. We conducted a network meta-analysis to compare short-term postoperative complications associated with preoperative exposure to these agents in patients undergoing colorectal surgery. Methods: We systematically searched PubMed, Web of Science, and the Cochrane Library through September 15, 2025, for cohort studies of adults with UC who were exposed to biologic or small-molecule therapy within 12 weeks prior to surgery. Interventions included biologic therapy, small-molecule therapy, and no biologic or small-molecule therapy (control). The primary outcome was overall postoperative complications at 30 and 90 days. Venous thromboembolism (VTE) was assessed as a key secondary outcome. Random-effects network meta-analysis was performed using risk ratios (RRs) with 95% confidence intervals (CIs). Results: Sixteen retrospective cohort studies involving 3235 patients were included. At 30 days, ustekinumab and tofacitinib were associated with lower overall postoperative complication rates than control (RR: 0.29; 95% CI: 0.09-0.96; and RR: 0.66; 95% CI: 0.46-0.96, respectively). Anti-tumor necrosis factor (TNF) therapy was associated with higher complication rates compared with vedolizumab, ustekinumab, and tofacitinib at 30 days (RR: 1.27; 95% CI: 1.00-1.63; RR: 3.67; 95% CI: 1.12-12.03; and RR: 1.61; 95% CI: 1.14-2.27, respectively). At 90 days, anti-TNF therapy was associated with higher complication rates than control (RR 1.20, 95% CI 1.03-1.40), although the 90-day analysis was based on limited data. VTE rates were similar across treatments at both time points. Conclusion: Preoperative ustekinumab and tofacitinib were associated with fewer 30-day postoperative complications than control or anti-TNF therapy, while vedolizumab was associated with fewer complications than anti-TNF therapy. At 90 days, anti-TNF therapy was associated with higher complication rates compared with control. These findings, particularly at 90 days based on limited data, should be interpreted with caution and require confirmation in well-designed prospective studies with rigorous adjustment for confounding factors.
- 5 August 2026
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 20 (8)
Comparative risk of postoperative complications in ulcerative colitis patients following preoperative advanced therapies: a network meta-analysis with meta-regression
Background: The expanding use of biologic and small-molecule therapies for ulcerative colitis (UC) has raised concerns regarding perioperative safety. We conducted a network meta-analysis to compare short-term postoperative complications associated with preoperative exposure to these agents in patients undergoing colorectal surgery. Methods: We systematically searched PubMed, Web of Science, and the Cochrane Library through September 15, 2025, for cohort studies of adults with UC who were exposed to biologic or small-molecule therapy within 12 weeks prior to surgery. Interventions included biologic therapy, small-molecule therapy, and no biologic or small-molecule therapy (control). The primary outcome was overall postoperative complications at 30 and 90 days. Venous thromboembolism (VTE) was assessed as a key secondary outcome. Random-effects network meta-analysis was performed using risk ratios (RRs) with 95% confidence intervals (CIs). Results: Sixteen retrospective cohort studies involving 3235 patients were included. At 30 days, ustekinumab and tofacitinib were associated with lower overall postoperative complication rates than control (RR: 0.29; 95% CI: 0.09-0.96; and RR: 0.66; 95% CI: 0.46-0.96, respectively). Anti-tumor necrosis factor (TNF) therapy was associated with higher complication rates compared with vedolizumab, ustekinumab, and tofacitinib at 30 days (RR: 1.27; 95% CI: 1.00-1.63; RR: 3.67; 95% CI: 1.12-12.03; and RR: 1.61; 95% CI: 1.14-2.27, respectively). At 90 days, anti-TNF therapy was associated with higher complication rates than control (RR 1.20, 95% CI 1.03-1.40), although the 90-day analysis was based on limited data. VTE rates were similar across treatments at both time points. Conclusion: Preoperative ustekinumab and tofacitinib were associated with fewer 30-day postoperative complications than control or anti-TNF therapy, while vedolizumab was associated with fewer complications than anti-TNF therapy. At 90 days, anti-TNF therapy was associated with higher complication rates compared with control. These findings, particularly at 90 days based on limited data, should be interpreted with caution and require confirmation in well-designed prospective studies with rigorous adjustment for confounding factors.
- Open Access
- 24 June 2026
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 71 (10) , 5037-5048
Navigating Treatment Selection in Acute Severe Ulcerative Colitis: A Prospective Mixed Method Analysis of Factors Influencing Patient Decision-Making
Acute severe ulcerative colitis (ASUC) is a life-threatening medical emergency necessitating immediate hospitalization and rapid initiation of therapy. For decades, intravenous (IV) corticosteroids have remained first-line, with rescue therapies reserved for patients who are corticosteroid-refractory. However, the therapeutic landscape has evolved, shifting toward earlier initiation of advanced therapy. This study analyzes factors influencing patient decision-making for treatment of ASUC. In this prospective, mixed-methods study, patients with ASUC who were infliximab and Janus kinase inhibitor naïve were enrolled. Participants were presented with educational resources on IV corticosteroids, upadacitinib, and infliximab and then asked to choose between continuing IV corticosteroids alone or starting early initiation of advanced therapy in addition to IV corticosteroids. Factors influencing their preferences were captured via semi-structured interviews, and clinical outcomes were followed. Eleven patients were prospectively enrolled. Analysis of semi-structured interviews revealed five dominant themes influencing treatment decision-making: (1) reliance on physician expertise, (2) contextualized treatment selection, (3) concrete risk assessment, (4) empathetic individualization, and (5) strong preference for oral therapy. Notably, we observed significant discordance between patient treatment preferences and medication initiated following discussion between the participant and their primary clinical team, particularly among participants favoring upadacitinib. These five principal themes offer actionable opportunities to assist patients in making well-informed decisions regarding ASUC therapy. Clinicians should utilize these insights to develop evidence-based patient decision aids that specifically address patient priorities. While patients often prioritize oral therapy, their choices often diverge from the therapy initiated after discussing with their primary clinical team. Future efforts should focus on bridging this discordance by integrating patient priorities with available evidence into the clinical decision-making process.
- 24 June 2026
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 71 (10) , 5037-5048
Open AccessNavigating Treatment Selection in Acute Severe Ulcerative Colitis: A Prospective Mixed Method Analysis of Factors Influencing Patient Decision-Making
Acute severe ulcerative colitis (ASUC) is a life-threatening medical emergency necessitating immediate hospitalization and rapid initiation of therapy. For decades, intravenous (IV) corticosteroids have remained first-line, with rescue therapies reserved for patients who are corticosteroid-refractory. However, the therapeutic landscape has evolved, shifting toward earlier initiation of advanced therapy. This study analyzes factors influencing patient decision-making for treatment of ASUC. In this prospective, mixed-methods study, patients with ASUC who were infliximab and Janus kinase inhibitor naïve were enrolled. Participants were presented with educational resources on IV corticosteroids, upadacitinib, and infliximab and then asked to choose between continuing IV corticosteroids alone or starting early initiation of advanced therapy in addition to IV corticosteroids. Factors influencing their preferences were captured via semi-structured interviews, and clinical outcomes were followed. Eleven patients were prospectively enrolled. Analysis of semi-structured interviews revealed five dominant themes influencing treatment decision-making: (1) reliance on physician expertise, (2) contextualized treatment selection, (3) concrete risk assessment, (4) empathetic individualization, and (5) strong preference for oral therapy. Notably, we observed significant discordance between patient treatment preferences and medication initiated following discussion between the participant and their primary clinical team, particularly among participants favoring upadacitinib. These five principal themes offer actionable opportunities to assist patients in making well-informed decisions regarding ASUC therapy. Clinicians should utilize these insights to develop evidence-based patient decision aids that specifically address patient priorities. While patients often prioritize oral therapy, their choices often diverge from the therapy initiated after discussing with their primary clinical team. Future efforts should focus on bridging this discordance by integrating patient priorities with available evidence into the clinical decision-making process.
- Open Access
- 23 June 2026
- Published by Springer Nature in International Journal of Colorectal Disease
- Vol. 41 (1)
Diversion proctitis during staged restorative proctocolectomy with ileal pouch anal anastomosis is not associated with subsequent cuffitis
The aim of this study was to assess the impact of diversion proctitis (DP) between the first and second surgical stage on pouch outcomes in patients with ulcerative colitis (UC) who underwent three-stage restorative proctocolectomy (RPC) with ileal pouch anal anastomosis (IPAA). We conducted a retrospective chart review of patients with UC who underwent three stage RPC with IPAA followed by at least one pouchoscopy at Mount Sinai Hospital between 1/2008 and 12/2020. DP was defined as the presence of mucosal atrophy and lymphoid hyperplasia on proctectomy specimen as noted by the reporting pathologist. The primary outcome was cuffitis defined as ulceration of the cuff as reported during pouchoscopy. Continuous and categorical variables were analyzed with t-tests and chi-squared tests, respectively. Of the 281 patients included in this study, 68 (24.2%) were found to have DP. Age, sex, race, ethnicity, anastomosis type, and disease duration were not significant risk factors for DP development. More patients with vs without DP had evidence of severe disease pre-colectomy with admission for acute severe ulcerative colitis, steroids, and infliximab, though this did not reach statistical significance. A significantly greater proportion of patients with vs without DP required rectal therapy between the first and second surgical stages (32.4% vs 19.2%, p = 0.02). There was no significant difference in the development of cuffitis among patients with vs without DP (19.1% vs 14.1%, p = 0.32). The occurrence of DP between the first and second surgical stage of RPC with IPAA is significantly associated with the need for rectal therapy; however, is not associated with subsequent cuffitis.
- 23 June 2026
- Published by Springer Nature in International Journal of Colorectal Disease
- Vol. 41 (1)
Open AccessDiversion proctitis during staged restorative proctocolectomy with ileal pouch anal anastomosis is not associated with subsequent cuffitis
The aim of this study was to assess the impact of diversion proctitis (DP) between the first and second surgical stage on pouch outcomes in patients with ulcerative colitis (UC) who underwent three-stage restorative proctocolectomy (RPC) with ileal pouch anal anastomosis (IPAA). We conducted a retrospective chart review of patients with UC who underwent three stage RPC with IPAA followed by at least one pouchoscopy at Mount Sinai Hospital between 1/2008 and 12/2020. DP was defined as the presence of mucosal atrophy and lymphoid hyperplasia on proctectomy specimen as noted by the reporting pathologist. The primary outcome was cuffitis defined as ulceration of the cuff as reported during pouchoscopy. Continuous and categorical variables were analyzed with t-tests and chi-squared tests, respectively. Of the 281 patients included in this study, 68 (24.2%) were found to have DP. Age, sex, race, ethnicity, anastomosis type, and disease duration were not significant risk factors for DP development. More patients with vs without DP had evidence of severe disease pre-colectomy with admission for acute severe ulcerative colitis, steroids, and infliximab, though this did not reach statistical significance. A significantly greater proportion of patients with vs without DP required rectal therapy between the first and second surgical stages (32.4% vs 19.2%, p = 0.02). There was no significant difference in the development of cuffitis among patients with vs without DP (19.1% vs 14.1%, p = 0.32). The occurrence of DP between the first and second surgical stage of RPC with IPAA is significantly associated with the need for rectal therapy; however, is not associated with subsequent cuffitis.
- 9 March 2026
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 32 (7) , 1298-1303
Fecal calprotectin is an accurate noninvasive screening tool for pouchitis
Background: Pouchitis is the most common complication after ileal pouch anal anastomosis (IPAA), yet symptoms are non-specific, and diagnosis typically requires pouchoscopy. Fecal calprotectin (FC) is an established inflammatory bowel disease biomarker, but optimal thresholds and diagnostic performance across distinct pouch phenotypes remain unclear. Methods: We performed an analysis of a prospectively maintained IPAA registry (2022-2025) at Mount Sinai Hospital. Adults with ulcerative colitis who had underwent total proctocolectomy with IPAA and had FC testing within ±90 days of pouchoscopy were included. Phenotypes were categorized as normal pouch (NP), acute pouchitis (AP), chronic pouchitis (CP), or Crohn’s disease–like pouch inflammation (CDLPI). FC was compared across phenotypes and tested for associations with endoscopic Pouchitis Disease Activity Index (PDAI) sub-score, histologic activity, and symptoms using non-parametric tests, Spearman correlation, log-linear regression, and receiver operating characteristic analysis. Results: Among 163 patients, FC differed significantly across pouch phenotypes (P <.01) with a median value of 50.5 µg/g in NP, 244 µg/g in AP, 370.5 µg/g in CP, and 231.5 µg/g in CDLPI. FC distinguished between inflammatory and normal pouches with an area under the curve (AUC) of 0.82, with an optimal threshold of ∼167 µg/g (specificity, 94%). FC correlated significantly with endoscopic PDAI sub-scores (Spearman ρ = 0.45, P <.001), and predicted severe endoscopic activity with an AUC of 0.82 and an optimal cutoff of 280 µg/g. Conclusion: FC is accurate for detecting and grading pouch inflammation. Thresholds near 167 and 280 µg/g reliably discriminate normal from inflamed pouches and mild from severe endoscopic disease, respectively.
- 9 March 2026
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 32 (7) , 1298-1303
Fecal calprotectin is an accurate noninvasive screening tool for pouchitis
Background: Pouchitis is the most common complication after ileal pouch anal anastomosis (IPAA), yet symptoms are non-specific, and diagnosis typically requires pouchoscopy. Fecal calprotectin (FC) is an established inflammatory bowel disease biomarker, but optimal thresholds and diagnostic performance across distinct pouch phenotypes remain unclear. Methods: We performed an analysis of a prospectively maintained IPAA registry (2022-2025) at Mount Sinai Hospital. Adults with ulcerative colitis who had underwent total proctocolectomy with IPAA and had FC testing within ±90 days of pouchoscopy were included. Phenotypes were categorized as normal pouch (NP), acute pouchitis (AP), chronic pouchitis (CP), or Crohn’s disease–like pouch inflammation (CDLPI). FC was compared across phenotypes and tested for associations with endoscopic Pouchitis Disease Activity Index (PDAI) sub-score, histologic activity, and symptoms using non-parametric tests, Spearman correlation, log-linear regression, and receiver operating characteristic analysis. Results: Among 163 patients, FC differed significantly across pouch phenotypes (P <.01) with a median value of 50.5 µg/g in NP, 244 µg/g in AP, 370.5 µg/g in CP, and 231.5 µg/g in CDLPI. FC distinguished between inflammatory and normal pouches with an area under the curve (AUC) of 0.82, with an optimal threshold of ∼167 µg/g (specificity, 94%). FC correlated significantly with endoscopic PDAI sub-scores (Spearman ρ = 0.45, P <.001), and predicted severe endoscopic activity with an AUC of 0.82 and an optimal cutoff of 280 µg/g. Conclusion: FC is accurate for detecting and grading pouch inflammation. Thresholds near 167 and 280 µg/g reliably discriminate normal from inflamed pouches and mild from severe endoscopic disease, respectively.
- Open Access
- 1 February 2026
- Published by Taylor & Francis in Journal of Inflammation Research
- Vol. ume 19, 1-6
Optimal Antibiotic Selection for the Treatment of Pouchitis After Ileal Pouch-Anal Anastomosis
Background: Pouchitis is the most common complication following ileal pouch-anal anastomosis for ulcerative colitis. Antibiotics remain the cornerstone of therapy for acute and chronic antibiotic dependent pouchitis, though evidence guiding their optimal use is limited. Material and Methods: A comprehensive literature search of PubMed, MEDLINE, Embase, and Google Scholar was conducted from database inception through October 2025 to identify studies evaluating antibiotic therapy for acute pouchitis. Eligible studies included randomized controlled trials, cohort studies, and observational series reporting clinical, endoscopic, or histologic outcomes. Data were extracted from 10 studies on study design, antibiotic regimen, efficacy, safety, and recurrence. Results: Data on the optimal selection of antibiotics for pouchitis is limited. Ciprofloxacin and metronidazole are the most extensively studied and commonly prescribed antibiotics. In a randomized clinical trial, ciprofloxacin demonstrated superior efficacy and tolerability compared with metronidazole. Rifaximin and vancomycin show potential benefit in selected cases. Conclusion: Antibiotic therapy provides rapid and effective symptom control in most patients with acute pouchitis. Ciprofloxacin should be considered first-line, with metronidazole or combination therapy reserved for non-responders.
- 1 February 2026
- Published by Taylor & Francis in Journal of Inflammation Research
- Vol. ume 19, 1-6
Open AccessOptimal Antibiotic Selection for the Treatment of Pouchitis After Ileal Pouch-Anal Anastomosis
Background: Pouchitis is the most common complication following ileal pouch-anal anastomosis for ulcerative colitis. Antibiotics remain the cornerstone of therapy for acute and chronic antibiotic dependent pouchitis, though evidence guiding their optimal use is limited. Material and Methods: A comprehensive literature search of PubMed, MEDLINE, Embase, and Google Scholar was conducted from database inception through October 2025 to identify studies evaluating antibiotic therapy for acute pouchitis. Eligible studies included randomized controlled trials, cohort studies, and observational series reporting clinical, endoscopic, or histologic outcomes. Data were extracted from 10 studies on study design, antibiotic regimen, efficacy, safety, and recurrence. Results: Data on the optimal selection of antibiotics for pouchitis is limited. Ciprofloxacin and metronidazole are the most extensively studied and commonly prescribed antibiotics. In a randomized clinical trial, ciprofloxacin demonstrated superior efficacy and tolerability compared with metronidazole. Rifaximin and vancomycin show potential benefit in selected cases. Conclusion: Antibiotic therapy provides rapid and effective symptom control in most patients with acute pouchitis. Ciprofloxacin should be considered first-line, with metronidazole or combination therapy reserved for non-responders.
- 8 November 2025
- Published by Elsevier in Clinical Gastroenterology and Hepatology
- Vol. 24 (9) , 2610-2612
Comparable 12-week and Superior 24-week Remission With Risankizumab vs Ustekinumab for Crohn’s-like Disease of the Pouch
- 8 November 2025
- Published by Elsevier in Clinical Gastroenterology and Hepatology
- Vol. 24 (9) , 2610-2612
Comparable 12-week and Superior 24-week Remission With Risankizumab vs Ustekinumab for Crohn’s-like Disease of the Pouch
- 13 July 2025
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 19 (9)
Scoring indices for assessing endoscopic disease activity in acute severe ulcerative colitis: a systematic review
Background and aims: Endoscopy is important for assessing disease severity and potentially predicting treatment response in acute severe ulcerative colitis (ASUC). We aimed to identify and determine the operating properties of existing endoscopic indices/items used to assess disease activity in ASUC. Methods: MEDLINE, Embase, and Cochrane CENTRAL were searched from database inception to April 17, 2024 to identify individual items and scoring indices used to evaluate endoscopic disease activity in patients with ASUC. Subsequently, we performed another comprehensive search from database inception to July 29, 2024 to identify studies that assessed the validity, reliability, feasibility, and responsiveness of the identified items and scoring indices. Results: We identified 18 studies that reported endoscopic measures in patients with ASUC, including Endoscopic Activity Index, Mayo endoscopic subscore (MES), Severe Endoscopic Lesions, Ulcerative Colitis Endoscopic Index of Severity (UCEIS), and the Degree of Ulcerative Colitis Burden of Luminal Inflammation (DUBLIN) score or sub-components of these indices. A total of 33 studies evaluated the operating properties of the MES, UCEIS, and DUBLIN score in ASUC. The MES and the UCEIS demonstrated adequate discriminant construct validity, convergent construct validity, and responsiveness. Feasibility or reliability were not assessed for these scores. The DUBLIN score demonstrated indeterminate discriminant construct validity and convergent construct validity with limited data. Responsiveness, feasibility, and reliability were not assessed for this score. Conclusions: These results highlight the need for a validated endoscopic score that can accurately describe and quantify the severity of endoscopic lesions and potentially predict outcomes in ASUC patients.
- 13 July 2025
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 19 (9)
Scoring indices for assessing endoscopic disease activity in acute severe ulcerative colitis: a systematic review
Background and aims: Endoscopy is important for assessing disease severity and potentially predicting treatment response in acute severe ulcerative colitis (ASUC). We aimed to identify and determine the operating properties of existing endoscopic indices/items used to assess disease activity in ASUC. Methods: MEDLINE, Embase, and Cochrane CENTRAL were searched from database inception to April 17, 2024 to identify individual items and scoring indices used to evaluate endoscopic disease activity in patients with ASUC. Subsequently, we performed another comprehensive search from database inception to July 29, 2024 to identify studies that assessed the validity, reliability, feasibility, and responsiveness of the identified items and scoring indices. Results: We identified 18 studies that reported endoscopic measures in patients with ASUC, including Endoscopic Activity Index, Mayo endoscopic subscore (MES), Severe Endoscopic Lesions, Ulcerative Colitis Endoscopic Index of Severity (UCEIS), and the Degree of Ulcerative Colitis Burden of Luminal Inflammation (DUBLIN) score or sub-components of these indices. A total of 33 studies evaluated the operating properties of the MES, UCEIS, and DUBLIN score in ASUC. The MES and the UCEIS demonstrated adequate discriminant construct validity, convergent construct validity, and responsiveness. Feasibility or reliability were not assessed for these scores. The DUBLIN score demonstrated indeterminate discriminant construct validity and convergent construct validity with limited data. Responsiveness, feasibility, and reliability were not assessed for this score. Conclusions: These results highlight the need for a validated endoscopic score that can accurately describe and quantify the severity of endoscopic lesions and potentially predict outcomes in ASUC patients.
- 3 July 2025
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 19 (7)
ECCO Topical Review on Pouch Disorders
Background: Pouch disorders are common and may present with symptoms of increased stool frequency, urgency, incontinence, pelvic cramping, obstructed defecation, and perianal drainage, which can result in poor sleep, fatigue, and disability. This topical review aims to offer expert consensus practice recommendations for the diagnosis and management of the most common inflammatory, functional, structural, and neoplastic J-pouch disorders. Methods: A multidisciplinary panel of gastroenterologists and colorectal surgeons performed a systematic review of the relevant literature on pouch disorders and developed current practice positions. Results: Seventeen current practice positions were developed on the diagnosis and management of inflammatory, functional, structural, and neoplastic pouch disorders. Conclusions: A multidisciplinary approach is essential for the diagnosis and management of pouch disorders.
- 3 July 2025
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 19 (7)
ECCO Topical Review on Pouch Disorders
Background: Pouch disorders are common and may present with symptoms of increased stool frequency, urgency, incontinence, pelvic cramping, obstructed defecation, and perianal drainage, which can result in poor sleep, fatigue, and disability. This topical review aims to offer expert consensus practice recommendations for the diagnosis and management of the most common inflammatory, functional, structural, and neoplastic J-pouch disorders. Methods: A multidisciplinary panel of gastroenterologists and colorectal surgeons performed a systematic review of the relevant literature on pouch disorders and developed current practice positions. Results: Seventeen current practice positions were developed on the diagnosis and management of inflammatory, functional, structural, and neoplastic pouch disorders. Conclusions: A multidisciplinary approach is essential for the diagnosis and management of pouch disorders.